EMA Withdrawn: Macugen (pegaptanib) — PharmaSwiss Ceska Republika s.r.o

View source ↗

Summary

EMA has withdrawn Macugen (pegaptanib) for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Status: Withdrawn. Therapeutic area: Wet Macular Degeneration. MAH: PharmaSwiss Ceska Republika s.r.o. Decision date: 20/07/2016